Objectives: There is no standardized treatment modality or a generally accepted guideline in cesarean scar pregnancy (CSP) treatment. The aim of this study is to retrospectively evaluate the outcomes of the different treatment modalities used in CSP treatment.
INTRODUCTION
Cesarean rates have shown a significant increase in the last two decades although all the medical precautions are taken all over the World [1] . Parallel to this increase, cesarean rates in Turkey unprecedentedly escalated from 21 percent in 2002 to 53 percent in 2015 [2] . Although these rates are higher in Turkey, cesarean rates were 28 percent in the upper-income group, 32 percent in the upper-middle-income group and 17 percent in all over the world according to the WHO health statistics between 2007 and 2014 [3] . As the primary cesarean rates increase, the complications in the subsequent pregnancies also increase. Among these complications, cesarean scar pregnancies (CSP) and placental invasion anomalies are the most important ones because of the catastrophic pregnancy outcomes [4, 5] .
Cesarean scar pregnancy was first described in 1978 [6] . Although it has been mentioned with many different names, CSP has become the most common definition in recent years [7, 8] . There was a significant increase in CSPs due to the rise in the rates of cesarean section [9] . The probability of CSP in a pregnant patient who had a previous cesarean section is approximately 1 in 2000 pregnancies [10] . Although it is mentioned in the literature that the diagnosis of CSP is problematic, it can be diagnosed if attention is paid to implantation localization [11] . The difficult part is to make a treatment plan on a subject where the treatment is not standardized, and there are no generally accepted guidelines worldwide. Patients who demand the continuation of their pregnancy, there is a dangerous process that goes from morbidly adherent placenta (MAP) to maternal mortality [12] .
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In this study, a retrospective analysis of thirty-one cesarean scar pregnancies which we treated in the last six years, has been done in our university hospital. The outcomes of different CSP treatment modalities and normal pregnancies or recurrent after the treatments in clinical follow-up were analyzed.
MATERIALS AND METHODS
This article includes retrospective data from 31 CSP patients who were examined in Uludag University Hospital Bursa, Turkey between May 2011 and February 2017. Weekly or monthly monitored β-HCG (human chorionic gonadotropin) levels in patient records were analyzed, and timeline graphics of each patient were prepared. Transvaginal ultrasonographic evaluations (Philips ClearVue 650, Philips Healthcare, The Netherlands) during diagnosis, treatment, and follow-up were taken from the patient files. The presence or absence of fetal heart activity (FHA) was also extracted from the patient records.
Since there is no standard definition for CSP diagnosis, the presence of all clinical findings which were described below is used to diagnose CSP [4] .
1. An empty uterine cavity and a closed and empty cervical canal. 2. The placenta ± a gestational sac embedded in the hysterotomy scar 3. A rich vascular pattern in the area of the cesarean scar with a positive pregnancy test 4. Absent myometrial layer between the gestational sac and the bladder 5. A triangular or rounded gestational sac that fills the niche of the scar 6. The presence of embryonic pole ± yolk sac with or without heart activity. Treatment options are offered to each patient after the CSP was diagnosed. Details of the advantages and complications of each treatment are provided. Their clinician decided assignment of the women to one of the six treatment methods. The treatment decision is reported to the patient, and the patient's informed written consent is obtained. Patients are monitored with the pelvic examination, B-HCG test, and ultrasonography in our outpatient clinic once in a week or month regularly for up to 2 years after the treatment. Women were reevaluated by ultrasonography for isthmocele before their subsequent pregnancy.
There were six primary treatment modalities which were used in cesarean scar pregnancies in our clinic. These were; Observational approach, Dilatation, and Curettage (D/C) procedure, D/C plus Systemic Methotrexate (MTX) Therapy, Systemic MTX therapy, Local MTX Therapy, and Combined Methotrexate Therapy. 50 mg/m 2 MTX via intramuscular administration was used for systemic MTX therapy. An oocyte retrieval needle with 25 mg MTX was used for the local MTX therapy. Details of the procedures are defined in the Supplementary Material 1. 
Statistical Analysis and Ethical Implications

RESULTS
Thirty-one CSP patients detected in our hospital records within six years. Demographic characteristics of the patients and the main aspects of the treatments are shown in Table 1 . Six treatment modalities used in our clinic are explained in detail in Figure 1 .
FHA:(+) CSP patients
Fetal heart activity was positive in 18 patients (58.06%). Patient-13 was evaluated with the observational approach because of her request for the continuation of her pregnancy by undertaking all the risks.
We performed a D/C procedure to five patients (Patient 3, 10, 17, 21 and 26). 
FHA:(-) CSP patients
There was only one patient (Patient 5) who were treated with the observational approach.
Five patients (Patient 7, 16, 18, 19 and 29) underwent a D/C procedure, and all of them were treated. Patient 7 was diagnosed with recurrent CSP after 100 days from the D/C procedure. Systemic MTX and D/C procedure were administrated, and she was treated in 21 days.
Only Patient 1 was treated with D/C procedure plus systemic MTX therapy together in FHA:(-) CSP patients.
There were two patients (Patient 14 and 28) who received local MTX therapy in FHA:(-) CSP patients.
Systemic MTX therapy was administered to Patient 8, 11 and 27 (Fig. 2) . However, an urgent revision curettage was required in Patient 11 after 55 days from the CSP treatment due to the excessive vaginal bleeding. Patient 27 conceived 623 days after the CSP treatment.
Combined MTX therapy was performed to Patient 15. However, an additional revision curettage had to be performed 28 days after the CSP treatment due to the abundant vaginal bleeding. She was treated in 47 days. 74 days later this woman underwent a laparoscopic cesarean scar defect (isthmocele) excision with an indication of postmenstrual spotting and pelvic pain. Detailed timeline graphics of all the CSP patients are shown in detail in Supplementary Material 2.
Patients conceived in clinical follow-up after the CSP treatment
Nine women conceived in clinical follow-up after B-HCG levels were negative in their first CSP treatments (Fig. 2) . Three women (Patient 3, 7 and 10) were diagnosed as CSP again. The remaining six patients (Patient 4, 5, 6, 9, 24 and 27) were conceived spontaneously on clinical follow-up (Fig. 3) . Five patients had regular pregnancy follow-up and underwent cesarean section at 33rd gestational weeks in patient 4, 35th weeks in patient 6, 34th weeks in patient 9, 35th weeks in patient 24 and 34th weeks in patient 27 respectively. Patient 5 was still pregnant at the time of writing this article. Perinatal and neonatal outcomes of the patients who conceived after the CSP treatments are shown in Table 2 . Abnormal placental invasion or morbidly adherent placenta was not found in pregnancies of these patients. However, an incomplete rupture observed at the previous cesarean scar site during cesarean section in 3 patients (Patient 6, 9 and 27).
Recurrent CSP patients
After successful treatment of the CSPs, three patients (Patient 3, 7 and 10) were detected as recurrent CSP in their next pregnancy (Fig. 2) . Patient 7 and Patient-10 treated with D/C (As their gestational sac were adjacent to the cervical www. journals.viamedica.pl/ginekologia_polska (P-4, P-5, P-6, P-9, P-24 and P-27) Perinatal outcomes are on the Table 2 5 patients wanted to become www. journals.viamedica.pl/ginekologia_polska canal) plus systemic MTX therapy and Patient 3 with combined MTX therapy. Detailed timeline graphics of recurrent CSP cases are shown in Figure 4 .
DISCUSSION
With the increase of the cesarean rates, two main clinical conditions which are early placenta accreta and CSP have threatened the subsequent pregnancy of the women in recent years. Both of these complications may risk women's life [13] . While placental invasion abnormalities have long been a primary concern of obstetrics, the definition of CSP is a new clinical entity. As cesarean rates increase, more patients are diagnosed with CSP every year [5] .
There are two fundamental problems in managing CSPs. The first problem is the diagnose, which is really difficult for CSPs especially for clinicians working in the primary care centers [14] . The second and the main problem is the treatment. Experiences about diagnosis are increasing day by day. However, the same situation cannot be applied to the treatment since there are no established guidelines in CSP treatment. In a study, combined local and systemic MTX treatment was found to be effective in 19 out of 26 cases [13] . In our data, five FHA:(+) CSP patients treated with combined treatment and all of them were treated. Two patients were pregnant afterward and delivered healthy babies via cesarean section.
The observational approach in CSP may have problematic consequences. In an article with 60 cases, high-rate hysterectomy had to be performed in cases which an observational approach was applied [15] . In our study, two patients requested the continuation of CSP pregnancy. We had to perform a hysterectomy to Patient 13. Patient 5 who had an FHA:(-) CSP, was spontaneously aborted in clinical follow-up. Similarly, in a recently published review, it was stated that CSPs with negative fetal heart activity might terminate spontaneously in expectant management [16] .
What is the most significant complication if the patient is diagnosed with CSP and wants to continue her pregnancy? The answer is inevitably morbidly adherent placenta. If an observational approach is applied, almost all of these women develop MAP. In a trial, ten CSP cases evaluated with the observational approach and MAP observed in all of them [9] . However, all of these patients undergoing the observational approach were FHA:(+) CSP patients. The observational approach was noted only in two women in our study. A placenta accreta with early diagnosis and a CSP case cannot be distinguished from each other histopathologically [17] . Both of these clinical entities will inevitably advance to MAP. Therefore, if an FHA:(+), CSP woman is to be followed up with an observational approach then she should be informed in detail about the catastrophic consequences of the treatment including hysterectomy.
The D/C procedure has always been up to date since the CSP definition was first introduced in the late seventies [4] . It is safer and cost-effective when done in guidance with USG [18, 19] . However, the most fundamental problem of this procedure is the distance between CSP sac and the cervical canal. Because the longer the range of CSP-cervical canal is, the harder it is to reach CSP with the curette. Therefore, the use of the D/C procedure alone in the treatment of CSP significantly reduces success rates [20] . In a recent review, it has stated that the D/C procedure could be successful only with the addition of other treatments such as uterine www. journals.viamedica.pl/ginekologia_polska 
There were 3 recurrent CSP cases (Patient-3, 7 and 10) detected from the patient files in clinical follow-up of the treated CSP patients. All of these three patients were treated with D/C procedure in their first caesarean scar pregnancies. After diagnosis of recurrent CSP, patient-3 were treated with combined MTX therapy. While patient 7 and 10 were treated with D/C plus systemic MTX therapy.
artery embolization or MTX therapy [21] . We have observed that the most significant handicap of the D/C procedure is recurrent CSP. Three recurrent CSP cases in our series were treated by only D/C procedure in their first CSP. However, CSP patients who treated with D/C plus systemic MTX therapy were all treated, and none of them recurred. It can be hy-www. journals.viamedica.pl/ginekologia_polska pothesized that while D/C procedure alone is inadequate in the treatment of CSP, D/C plus systemic MTX therapy may be useful. Since the recurrent CSP is ubiquitous after the D/C procedure, a recent trial has shown that the operative hysteroscopy is useful in such cases [22] .
Non-surgical treatments might also be of interest in the treatment of CSP. Uterine artery embolization may be useful in CSPs presenting with acute bleeding [23] . The most popular non-surgical treatment modality is a chemotherapeutic agent administration of a local injection into the CSP sac [24] . Two women who had FHA:(-) CSP, received local MTX treatment in our cohort. Complete cure was achieved in Patient 14 but Patient 28 has still complaints about vaginal spotting, and she is in the clinical evaluation process at the moment. Clinicians usually want to try the local treatment in locally accessible patients or in cases where CSP does not spread volumetrically. We think that some main anatomical measurements such as the volume of CSP, the distances between CSP-bladder, CSP-cervical canal, CSP-fundus uteri, and CSP-external cervical os should be evaluated to predict which CSP patient will be sufficient for the local treatment. Another point is that it is unknown why systemic MTX therapy has not been used with local MTX therapy and also it is unknown which treatment (local, systemic or combined) should be given to which patient.
Which CSPs can be advanced to the term is controversial. In a recent review, the concept of endogenous and exogenous growth has been put forward [25] . A CSP which has a potential for endogenous growth, can migrate towards the fundus and then reach the term. However, the CSP which has a potential for exogenous growth is expanding directly into the bladder and can lead to catastrophic outcomes. Although we did not perform any in our series, laparoscopic management of CSP in a previous cesarean section scar with exogenous growth can also be considered as an effective treatment method [26] .
Noninvasive treatments can be a factor in conceiving again in CSPs. Conducting pharmacological therapies rather than a destructive treatment as in D/C procedure may facilitate normal pregnancy in the clinical follow-up of the treated CSP patients. The absence of placental invasion anomalies in six pregnancies may be seen as a limitation of this study because at least one placental invasion anomaly would have to be observed according to similar retrospective studies [10] .
In conclusion, the treatment stages of CSP, which clinicians have encountered more and more in recent years, have not been standardized yet. Successful treatment of CSPs with different treatment modalities may be possible. The trials in this area consist of numerous retrospective analyzes as it is in our study and more randomized trials are needed to be done. 
